Brian Bares
Bares Capital Management
Bares Capital Management Iradimed Co stake
total: 156
Bares Capital Management IRMD trades
- Total transactions:
- 9
- New positions:
- 1
- Sold out:
- 1
- Added:
- 6
- Reduced:
- 1
- Held since:
- 2021 Q3
- Held for:
- 12 quarters
- Latest activity:
- 2024 Q3
According to 2025 Q3 report, Bares Capital Management doesn't hold any Iradimed Co (IRMD) shares. To date, the estimated cost basis is nearly $32.88 for "buy" trades and estimated average "sell" price is $44.41. Bares Capital Management first purchased IRMD in 2021 Q3, initially acquiring 61,786 shares. Since the initial investment in Iradimed Co (IRMD), Bares Capital Management has made 8 more transactions.
When did Bares Capital Management sell Iradimed Co (IRMD)?
Bares Capital Management sold off the entire Iradimed Co (IRMD) position in 2024 Q3.
When did Bares Capital Management buy Iradimed Co (IRMD)?
Bares Capital Management first invested in Iradimed Co (IRMD) in 2021 Q3 at the reported quarter-end price of $33.58 per share.
What's the cost basis of Bares Capital Management's IRMD stake?
The estimated cost basis for Iradimed Co (IRMD) stake is around $32.88 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $32.88
- Weighted AVG sell price:
- $44.41
Bares Capital Management's historical trades in Iradimed Co
9 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q3
|
0.00%
|
0
|
$43.94
|
|
-100% (-283,600)
|
-0.6%
|
|
2024 Q2
|
0.60%
|
283,600
|
$43.94
|
$12,461,384
|
+1.65% (+4,600)
|
+0.01%
|
|
2024 Q1
|
0.49%
|
279,000
|
$43.99
|
$12,273,210
|
+0.72% (+2,000)
|
+0%
|
|
2023 Q2
|
0.46%
|
277,000
|
$47.74
|
$13,223,980
|
-12.62% (-40,000)
|
-0.07%
|
|
2023 Q1
|
0.44%
|
317,000
|
$39.35
|
$12,473,950
|
+16.84% (+45,700)
|
+0.06%
|
|
2022 Q4
|
0.29%
|
271,300
|
$28.29
|
$7,675,077
|
+21.11% (+47,298)
|
+0.05%
|
|
2022 Q3
|
0.26%
|
224,002
|
$30.06
|
$6,734,000
|
+73.32% (+94,762)
|
+0.11%
|
|
2022 Q2
|
0.16%
|
129,240
|
$33.94
|
$4,386,000
|
+109.17% (+67,454)
|
+0.08%
|
|
2021 Q3
|
0.04%
|
61,786
|
$33.58
|
$2,075,000
|
new
|
+0.04%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.